Skip to content

Artificial intelligence-guided sensors for personalized pain medicine

A review paper by scientists at Indiana University Bloomington summarized recent engineering efforts in developing various sensors and devices for addressing challenges in the personalized treatment of pain. The new review paper, published on Sept. 13 in the journal Cyborg and Bionic Systems, critically examines the role of sensors and devices guided by artificial intelligence (AI) in the field of personalized pain medicine, highlighting their transformative impact on treatment outcomes and patient quality of life. Pain, a complex and subjective experience, markedly diminishes individual quality of life and imposes substantial burdens on healthcare systems. Despite the acknowledged universality and significance of pain, its accurate assessment and effective management pose persistent difficulties. “Personalized pain medicine aims to tailor pain treatment strategies for the specific needs and characteristics of an individual patient, holding the potential for improving treatment outcomes, reducing side… 

more »Sensors guided by artificial intelligence for personalized pain medicine

Medical Research Act passes Bundesrat

  • News

The Bundesrat passed the so-called Medical Research Act on Friday. The law has thus overcome the final political hurdle and can come into force as planned. The law is intended to strengthen Germany as a location for medical research. For example, clinical trials and the approval process for medicines and medical devices are to be simplified, de-bureaucratized, and accelerated. Standard contract clauses are intended to ensure this [...] Medical Research Act passes Bundesrat

FDA Approves Bristol Myers Squibb’s COBENFY

COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies Approval is supported by data from the EMERGENT clinical program demonstrating statistically significant reductions of schizophrenia symptoms The safety and tolerability profile of COBENFY has been established across acute and long-term trials in schizophrenia. COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M 1 and M 4 receptors in the brain without blocking D 2 receptors. Schizophrenia is a persistent and often disabling mental illness affecting how a person thinks, feels and behaves. 5 It is estimated to impact approximately 2.8 million people in the United States. 6 Symptoms typically first appear in early adulthood and present differently in each person, making symptoms difficult… 

more »FDA Approves Bristol Myers Squibb’s COBENFY

Opening of the exhibition “Dr. Future – Medical Technology from Dresden Science”

  • News

The COSMO Science Forum at the Kulturpalast Dresden will present the new exhibition “Dr. Future – Medical Technology from Dresden Science” starting October 1, 2024. Scientists from Dresden research institutions will present their current projects there and offer an interactive journey into the future of medicine. The exhibition “Dr. Future” shows how continuous research and innovation can improve people's quality of life and save lives. From prevention through diagnosis to surgery, the exhibition highlights the advances in medical technology made possible by the collaboration between engineering and medicine. Dresden scientists are contributing to the development of new treatment options with their inventions, which find application in both everyday life and medical facilities. Visitors to the exhibition can learn, for example, how artificial intelligence will support medical diagnosis in the future, what novel implants are made of textiles, and how new medical tests… 

more »Opening of the exhibition “Dr. Future – Medical Technology from Dresden Science”

Mitsubishi Tanabe Pharma America to Highlight Data

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations on investigational ND0612 in Parkinson’s disease (PD) will be shared at the 2024 International Congress of Parkinson’s Disease and Movement Disorders (MDS), being held September 27-October 1 in Philadelphia, Pa. ND0612 is being evaluated as a continuous, 24 hours/day subcutaneous infusion of liquid levodopa/carbidopa. MTPA’s posters will be presented in Exhibit Hall A on September 29, 1:00-3:00 p.m. ET: Presentation Details: Presentations include a range of data from the pivotal Phase 3 BouNDless trial (NCT04006210) evaluating ND0612 in people with PD experiencing motor fluctuations, utilizing data derived from patient-reported outcomes assessing quality of life and motor experiences of daily living, among other findings. Additionally, one-year outcomes from the ongoing open-label extension phase of the BouNDless trial will be presented.

Sudden Cardiac Death: DGK Calls for More Lay Resuscitation

On the occasion of World Heart Day on September 29, the German Society of Cardiology points to the significant need for improvement in the chain of survival in Germany. In particular, initial care and targeted patient transport in cases of sudden cardiac death can be improved. Heart teams trained to the best possible standard in intensive care medicine are also essential for the survival of those affected. In his presentation as part of the DGK Heart Days, Prof. Alexander Ghanem from Hamburg discussed the importance of the "Golden Hour of ROSC" – the critical 60-minute window in which survival chances can be maximized and brain damage minimized. He urgently called for measures to improve the rate of bystander CPR and emergency care. In Scandinavian countries, this rate is over 80%, while Germany, with around 40-50%, still has a lot of catching up to do. Better networking of emergency services with specialized clinics is also a key element. Even before or during transport,...

more »Sudden Cardiac Death: DGK Calls for More Bystander CPR

Vitamin D Test: Costs and Coverage

A vitamin D test can provide important information about your health status, but it is not always covered by health insurance companies[1]. Here are the most important points: Cost of the test – A vitamin D test typically costs between 20 and 30 euros[1].– For laboratory tests, the costs can rise to up to 65 euros[1]. Coverage by health insurance companies – Statutory health insurance companies only cover the costs if medically necessary[1].– Suspicion of vitamin D deficiency alone is not sufficient for cost coverage[1]. Medical indications Health insurance companies pay for the test in cases of:– Osteoporosis– Kidney diseases– Taking certain medications[1] Self-payer option – Patients can pay for the test themselves as an individual health service (IGeL)[1].– A conversation with the doctor is advisable to clarify the necessity of the test[1]. Alternatives to the test – Experts often recommend taking vitamin D preventively instead of a test[1].– The German Nutrition Society recommends a daily intake of 20 micrograms of vitamin D[1]. Sources:[1] vitamin-d-test-kosten-krankenkasse-27-9-24-101820847 https://www.augsburger-allgemeine.de/panorama/vitamin-d-test-kosten-krankenkasse-27-9-24-101820847

Deep-tech talent war escalates between Europe and North America

New report by Zeki Data breaks down competition within the deep-tech ecosystem A new global report on deep-tech talent, released today by Zeki Data, shows that the US produces three times as many deep-tech companies as the UK, while small European startups have a much higher concentration of highly skilled talent than in [...] Deep-tech talent war escalates between Europe and North America

Study Innovation Indicator 2024: Switzerland repeatedly takes 1st place

Innovation Indicator 2024 by Roland Berger and BDI analyzes and compares the innovation capabilities of 35 economies worldwide Switzerland, Singapore, and Denmark lead the ranking, followed by other small countries; large industrial nations only from 11th place USA continuously losing innovative strength; China as the only major industrial country with sustained upward momentum In terms of innovation capabilities [...] Study Innovation Indicator 2024: Switzerland repeatedly takes 1st place

Anemia diagnosis after chips and cola

(MedLabPortal) Cases of nutritional anemias in Germany are rare but increasing. Julie Schanz, Julia Knaus, and Nils Brökers, researchers at the University Medical Center Göttingen (UMG), drew attention to this at the German Congress for Laboratory Medicine (DKLM) in Bremen. The reason for this is that a one-sided diet leads to a deficiency in vitamin B12 or folic acid. However, these building blocks play a central role in the highly complex process of blood formation. Iron deficiency can also lead to anemia – sometimes also a consequence of a one-sided diet. For those affected, the consequences are more than frightening. "A patient came to us who practically lived on chips and cola while gaming on the PC for weeks," describes physician Brökers. "As a result of the existing anemia, he already showed neurological deficits; he could no longer see clearly." In such cases, the most important thing is primarily a... 

more »Anemia Diagnosis After Chips and Cola